On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies…
April 30, 2025 17:00 ET | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical…
April 30, 2025 16:30 ET | Source: LENZ Therapeutics, Inc. SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics,…
April 29, 2025 20:53 ET | Source: Mesoblast Limited NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;…
Almere, The NetherlandsApril 29, 2025, 6 p.m. CET Solid start of the year, Q1 sales supported by continued AI-related strength…
Kia posts 2025 Q1 global sales of 772,648 units, a 1.6% increase Y/yQ1 revenue at KRW 28.02 trillion, up 6.9%…
April 24, 2025 19:51 ET | Source: Alpha Teknova, Inc. HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova,…
April 24, 2025 17:00 ET | Source: Tarsus Pharmaceuticals, Inc IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals,…
April 24, 2025 16:30 ET | Source: CVRx, Inc. MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX)…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter](https://i2.wp.com/ml-eu.globenewswire.com/media/MTgyYjlhNDItMjcxOS00MmM0LWIyNzEtZTZlMDBhOWM0NjNiLTEwMTI2MjEtMjAyNS0wNC0yNC1lbg==/tiny/F-Hoffmann-La-Roche-Ltd.png?w=1920&resize=1920,19&ssl=1)
Group sales grew by 6%1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines…
